The Washington-based biopharmaceutical firm, currently traded on the Nasdaq as VNDA, maintains a portfolio centered on addressing complex, unmet medical needs. This appearance serves as part of the company’s ongoing engagement with investors and healthcare analysts following their recent development milestones. Kevin Moran, the company’s Senior Vice President and Chief Financial Officer, remains the primary point of contact for inquiries regarding the firm's strategic direction and upcoming presentations.
In section Releases
Vanda Pharmaceuticals to Present at B. Riley Securities Summit
Vanda Pharmaceuticals Inc. will outline its current clinical and commercial progress during a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit. The session is scheduled for Thursday, July 16, 2026, in Boston, gathering industry leaders to discuss emerging trends in biotechnology and medical innovation.
Comments (0)
No comments yet. Be the first!